0001104659-22-123467.txt : 20221201 0001104659-22-123467.hdr.sgml : 20221201 20221201083024 ACCESSION NUMBER: 0001104659-22-123467 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20221130 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221201 DATE AS OF CHANGE: 20221201 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MAXCYTE, INC. CENTRAL INDEX KEY: 0001287098 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 522210438 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40674 FILM NUMBER: 221437458 BUSINESS ADDRESS: STREET 1: 22 FIRSTFIELD ROAD STREET 2: SUITE 250 CITY: GAITHERSBURG STATE: MD ZIP: 20878 BUSINESS PHONE: 301-517-5556 MAIL ADDRESS: STREET 1: 22 FIRSTFIELD ROAD STREET 2: SUITE 250 CITY: GAITHERSBURG STATE: MD ZIP: 20878 FORMER COMPANY: FORMER CONFORMED NAME: MAXCYTE INC DATE OF NAME CHANGE: 20040415 8-K 1 tm2231548d1_8k.htm FORM 8-K
0001287098 false 0001287098 2022-11-30 2022-11-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 30, 2022

 

 

 

MaxCyte, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware 001-40674 52-2210438
(State or other jurisdiction of
incorporation)		 (Commission File Number) (IRS Employer
Identification No.)

 

9713 Key West Avenue, Suite 400

Rockville, Maryland 20850

(Address of principal executive offices, including zip code)

 

(301) 944-1700

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.01 par value   MXCT   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial account standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 5.02               Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Appointment of Patrick Balthrop as Director

 

On November 30, 2022, upon the recommendation of its Nominating and Corporate Governance Committee (the “Nominating Committee”), the Board of Directors (the “Board”) of MaxCyte, Inc. (the “Company”) appointed Patrick J. Balthrop, Sr. to serve as a Class II director. Mr. Balthrop will serve for the term expiring at the Company’s 2023 annual meeting of stockholders, and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal. Mr. Balthrop was also appointed as a member of the Nominating Committee. Mr. Balthrop was not selected as a director pursuant to any arrangements or understandings with the Company or with any other person.

 

Mr. Balthrop, 66, has more than three decades of experience in the healthcare sector, particularly in diagnostics, life science tools and medical devices. From 2004 until his retirement in 2014, Mr. Balthrop was President, Chief Executive Officer and a director of Luminex Corporation, a publicly held life science tools and molecular diagnostics company. From 2002 to 2004, he served as president of Fisher Healthcare, now a division of Thermo Fisher Scientific, Inc. He previously served for more than 20 years in roles of increasing responsibility with Abbott Laboratories, including as head of Abbott Vascular and Corporate VP of Worldwide Operations for Abbott Diagnostics. He currently serves as chairman of the board of the privately held life sciences companies Agendia, Inc. and Diagnostic Life Sciences and as director of the privately held life sciences company Pattern Biosciences. Within the past five years, he served as a director of the publicly held diagnostics company Oxford Immunotec Global PLC, including as its chairman from June 2019 until March 2021. He has also served as a member of the board of directors of Personalis, Inc., a publicly held cancer genomics company, from 2015 until March 2021. In January 2015, Mr. Balthrop founded and has since served as Principal of Apalachee Ventures, LLC, an investment and advisory firm. He also serves as executive advisor to Water Street Healthcare Partners, a healthcare-focused private equity firm. Mr. Balthrop holds a B.S. in Biology from Spring Hill College and an M.B.A. from the Kellogg School of Management at Northwestern University.

 

Upon his commencement of service as a director, Mr. Balthrop was granted a nonqualified stock option to purchase 100,000 shares of the Company’s common stock with an exercise price of $5.99 per share, which was the closing price of the Company’s common stock on the Nasdaq Global Market on the date of grant.  This option will vest and become exercisable over three years, with one-third of the shares vesting after 12 months, and the remainder vesting monthly over the following 24 months until the third anniversary of the date of grant, subject to Mr. Balthrop’s continuous service, as defined in the Company’s 2022 Equity Incentive Plan (the “Plan”), through each applicable vesting date.  Additionally, Mr. Balthrop will be entitled to receive a $40,000 annual retainer for his service as a director and a $5,000 annual retainer as a member of the Nominating Committee.  

 

The Company intends to enter into its standard form of indemnification agreement with Mr. Balthrop, the form of which was filed as Exhibit 10.8 to Amendment No. 1 to the Company’s Registration Statement on Form S-1, which was filed with the Securities and Exchange Commission on July 26, 2021.

 

There are no related party transactions between Mr. Balthrop and the Company that would require disclosure under Item 404(a) of Regulation S-K, and there are no family relationships between Mr. Balthrop and any director or executive officer of the Company.

 

Item 7.01Regulation FD Disclosure.

 

On December 1, 2022, the Company issued a press release announcing the appointment of Mr. Balthrop as a director of the Company. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

 

 

 

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
 No.  		   Description
   
99.1   Press Release dated December 1, 2022
104   Cover Page Interactive Data (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MaxCyte, Inc.
     
Dated: December 1, 2022 By: /s/ Doug Doerfler
    Doug Doerfler
    President and Chief Executive Officer

 

 

 

 EX-99.1 2 tm2231548d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

MaxCyte Appoints Patrick J. Balthrop as Non-Executive Director

 

Rockville, MD, 1 December, 2022: MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announces the appointment of Patrick J. Balthrop, Sr. to the company’s Board of Directors as non-executive director with immediate effect. Mr. Balthrop is also appointed as non-executive member of the Nominating and Corporate Governance Committee.

 

Mr. Balthrop has more than 35 years of experience in the healthcare sector, particularly in the life sciences segments of diagnostics, life science tools, and medical devices. He was CEO, President, and Director of Luminex Corporation (NASDAQ: LMNX) for over 10 years, quadrupling the company’s revenue in five years. Prior to this he was President of Fisher Healthcare (then Fisher Scientific). He held positions at Abbott Laboratories over a period of 20 years including head of Abbott Vascular and Corporate VP of Worldwide Operations for Abbott Diagnostics.

 

Mr. Balthrop currently serves as Chairman of the Board for both Agendia, Inc. and Discovery Life Sciences, and as Director of Pattern Biosciences. He has previously held board positions at publicly listed life science companies, including Oxford Immunotec Global (NASDAQ: OXFD), and Personalis, Inc. (NASDAQ: PSNL). Additionally, he serves as Executive Advisor to Water Street Healthcare Partners and is a Founding Principal of Apalachee Ventures.

 

Mr. Balthrop received an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University, and a B.S. in Biology from Spring Hill College.

 

“Patrick has an outstanding track-record of building, growing, and optimizing businesses in the life sciences sector, and we are delighted and honored to welcome him to our Board,” said Doug Doerfler, President and CEO of MaxCyte. “We look forward to drawing on his invaluable experience and insight as we continue to advance the next-generation of cell therapy discovery, development and commercialization."

 

Grant of options

 

Upon appointment, Mr. Balthrop has been granted 100,000 options over common stock, $0.01 par, of the Company ("Options"). These Options vest over three (3) years, with initial vesting of 1/3rd of the total after twelve (12) months, and the remainder vesting monthly over the following twenty-four (24) months. The Options have an exercise price of $5.99, equal to the closing price of MaxCyte's stock on 30 November, 2022.

 

Additional Disclosures

 

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies.

 

 

 

 

Mr Patrick James Balthrop, Sr. (aged 66) holds or has held the following current and former directorships in the past five years:

 

Current Directorships Former Directorships in the past five years
Agendia NV Chromacode, Inc
Apalachee Ventures, LLC Oxford Immunotec Global Limited
Discovery Life Sciences, LLC Oyster City Brewing Company, LLC
Made by the Water, LLC Personalis, Inc
Pattern Bioscience, Inc  

 

Save as set out above, no further information regarding Patrick Balthrop is required to be disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies.

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Patrick Balthrop
2 Reason for the notification
a) Position/status Non-Executive Directors
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name MaxCyte, Inc.
b) LEI 54930053YHXULRFCU991
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument  Options over common stock, $0.01 par, of the Company
b) Identification Code US57777K1060
c) Nature of the transaction Grant of Options
d) Price(s) and volume(s) 100,000 Options at an exercise price of $5.99
e)

Aggregated information

 

- Aggregated volume

 

- Price

N/A

 

N/A

 

N/A

f) Date of the transaction 30 November 2022
g) Place of the transaction Nasdaq Stock Exchange

 

 

 

 

 

 

About MaxCyte

 

MaxCyte is a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovative, cell-based research. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® technology, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™ GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. Learn more at maxcyte.com and follow us on Twitter and LinkedIn.

 

MaxCyte Contacts:

 

US IR Adviser 

Gilmartin Group 

David Deuchler, CFA 

+1 415-937-5400 

jr@maxcyte.com

 

US Media Relations 

Spectrum Seismic Collaborative 

Valerie Enes 

+1 408-497-8568 

valerie@spectrumscience.com

 

Nominated Adviser and Joint Corporate Broker 

Panmure Gordon 

Emma Earl / Freddy Crossley 

Corporate Broking 

Rupert Dearden 

+44 (0)20 7886 2500

 

UK IR Adviser 

Consilium Strategic Communications 

Mary-Jane Elliott 

Chris Welsh 

+44 (0)203 709 5700 

maxcyte@consilium-comms.com

 

 

 

 EX-101.SCH 3 mxct-20220630.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 mxct-20220630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 mxct-20220630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2231548d1_ex99-1img01.jpg GRAPHIC begin 644 tm2231548d1_ex99-1img01.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@!"0 M!DD >IIOG1?\]$_[Z%8FK:J@E^SQ-]P_.??TK*DU)8HFD=\(H))]JU5*3,I5 M8H[%9(V;:KJ3C. :5F51EB /7Y(6)#_ NZMS4=56: MY*QM^[3@>_O5U*$H3Y#*CB8U:?M%M=_@=%YT7_/1/^^A2JZ/G:RMC@X.<5Q% M]K26-H]Q(20O11U8^E6?AY=3WNE7]U<,6DEO68^WR)@?04.A)4W4>R#ZS'VJ MI+=W9U-W>6NGVKW5[0.!G[P[J? M8C(_&N,9>69PBJ/Q]QT/TKPOXX^+C?:O%X@/KM'ZD^E CV^P\0Z+J MMP;?3M8T^\F"[S';W*2,%Z9PI)QR/SK2KYQ^ W_(^W/_ &#I/_0XZ^CJ "BJ MRZA9/=&U6\MVN!UB$JEQ^&1@^'OQ"UF$7YL+U]PW*US=*KM^#L#^= ['U)1 M7R]H/C[Q7X%UP66IRWOI+1=9L?$&DP:GIT MPEMIURK8P0>A!'8@\4"+]%%% !12,RHI9F"JHR23@ 5\[_$OQWX@T[Q]J%KI M.N3Q62"+RTA<%1F-2E6)PX^T2#$ M:_S/X5H7=W!8VDMUPKQK6?$CZOJ4ETWRH?EC3^ZHZ"NS"X=U97 MZ(X<9BXT(V;U9K&_+$DMDGDDFJUY+)VOZIL<-]EA&^9AW M]%S[_P @:O:K'#IZ7$S *B,0J^ISP*]!\L*G(MSSXR=2DYOX2CI5P^EK@]_6NX\ P^3HMPN,9N"?\ QU:Y_P"PCTKK?"L7 MDZ;*OK,3^@KCQ%1.ERH]##T;5>=[F/\ %S_DE^M?[L7_ *.2O!_ _@]?%^F^ M((HE8W]I;I-:;3]YLG*GZCCZXKWCXN?\DOUK_=B_]')7G/[/G_(8UO\ Z]X_ M_0C7F'JG.>!_B3>>$-"UC3'+L6B+6*L,^5.2 >.PP2V/5?>JGAGPK+XBT/Q+ MXFU)YI(K*VE=)&;)FN"I.2>IQU/N1[UTWQ.^&TT7C.RGT>-FAUNX*%=ORPS$ MY;_@)&6]L-Z5Z5JWAZT\+?!_5=(LR62'3YMTA&#(Y4EF/U/Y=* /*O@-_P C M[<_]@Z3_ -#CJW\6O'NJW?B:;P[I%U-#:6Y$,@MR0T\IZ@D>98P3XWK \["0'TR%P#^-<7X@?78-6>TUV6Y^WVJB%A,^Y@!R!GN,'@Y/& M*^Q@0RAE((/(([U\R?&JYMKGXC7 MV5FB@CCF*G/S@$G\0"!^% 'M'B3PHGB M[P!;6BL8[Z.U22UE#8*R;!P3Z'H?S[5XQX#\8:A\/O%LVGZV)TM)'\J\ADR3 M$PZ.![9[=0>_%?1VC_\ ($L/^O:/_P!!%?/'QMU#2KWQJ([",&ZMXA'>3JV0 M[]EQZJ."?P[4 5_'GB_4_'OC!=-T>262R2;R;*&+CS6Z%S]??H/3FO5+?1S\ M,OA5J=R)#)JOVM\J@$_PJ6&/Q/>O+_@K?Z58^.5348P+F>,Q6K#@'\.]?0/BG1QX@\+:EI1^])(_"7CC;J)\BVN5-K.TG'E-D$$^F",'TR:]BU+X?3F^T0Q6RB,%./#G MPU2ST-Y)+V M" :Y:KBYODV.V@IJG'VGQ6U/"_@7XFF@\1W.AW-PS07L9DA5VSB5>>/JN?\ MOD5N_'O7WMK+3-$MYBCS,;F8*<':ORK^!);_ +YKSKQ'9R_#OXH,]HA$=KN-'OGA>Y@VEF MA8E3N4,,$@'H1VKZ_P!*TZ#2-)M-.MAB&UA6),]2%&,GWKYE^,/_ "5'5?I! M_P"B4H!'KOPJ\ ZMX(?56U.:SD%V(O+^SNS8V[\YRH_O"O/?'/Q"UOQ?XE.@ M^&I;A+(2>3$EL2KW+#JQ(_AZX'3')]OH:0,]NPC.&*':??'%?('A6TU>?Q3: MVNC70L]4+.D4CR>7M;:G7#07RRW$T5V'8.KAFS@?>Z\4 ?1,D,4NW MS(T?:@_G]*X9/!7B M=G5?[+D7)QDLN!^M>ZT5Z%''SI04(Q1Y6(RNG7J.I.3O\C*\/:'!H&DQ6<.& M?[TLF.7?N?\ #VKSKQ5HOB/5M7D-OI4_V2)B(SE?FYY;KW_E7K5%8TL3*G4= M2UV^YT5\'"K25&]HKL>(6'@3Q#=7T,$]F]M"S?/,Y!"#UP#S7L5KIT.GZ.FG MVRXCCB\M<]3QU/N3S5VBGB,7.O;FT2)PF I8:[AJWW,#^R9?[AK3TVV:V@9& M&"6S^@JY17,Y-[G:HI'+?$?2KW6_ .J:=IT!GNYA'Y<88#=B12>20.@-<3\& MO!VO^&-2U276=/:U2:%%C)D1MQ!.?NDUZ_14E"%02"0"0#M M8LK.(RW,]I)'$@(&YBI &3Q6U10!XC\(O _B3PWXOGO=7TQ[6W:R>(.9$;+% MT(&%)/0&M/XG?"BZ\2:FVN:')%]L= )[>5MHE(& RGIG P<#CK7K=% 'S!8 MZ3\4HU&A6T6O0P?<"%G2)1Z!R=H'T.*;?_![QG:SJL>G+>%D#O)%,F Q_A^8 M@DCUQ7U#10.YQ_B>3Q%9^!X;+P_ITEQJDL"P%ED51;C: S9)&3V&._/:O-_A MS\)-237_ .TO%-D88+4AX8&D5O.DSD$[2>!C.#U..V:]XHH$>#?$3X2ZO)XD MDU;PS;?:(;MS+)"CJC0R=21DC@GD8Z'/M7J7@6Z\13^'T@\3V#VVH6^$,K.C M"=>S?*3@^OY]^.GHH \F^(?P>'B"^GUG0YDAOY3NFMY>(Y3CJ"/NL??@GTKR MMO#OQ#T-FT^&RUZ%,_E?05K:P65I#:VT2Q00H$C11@*HX J:B@1Y'\>])M9O#=CJS, MJ7=O<>2G',BN"2OX;<_GZUS/P%T#[7KU[KDJ_N[*/RHO>1^I_!0?^^JM_&:/ MQ+XA\10Z=8:'JD^G6*962&TD9))& )((&#@8'US7IOP[\,?\(IX-M+"3'VJ3 M]_<'&/WC8R/P&%_"@9U5>"?%[P!KUYXJFUW3+&6^MKE$#K NYXV50N"HY(PH M.17O=% CS/X/W7BJ>PU"#Q(E^D=N(4M!>0&,[<-NP2 6Z+USVK#^(?P=NM1U M276O#/E^;,V^:T9]F7[LC'CD\D''/?M7M%% 'S$4^*PA.B&/Q#Y6?+V['(QZ M>9_=_P"!8KT/X6?#/5_"^HOJ^K7A@D9"BV4$N5;/>0C@X[ 9YYS7K5% PHHH MH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 ; 4444 %%%% !1110 4444 %%%% !1110!__9 end GRAPHIC 7 tm2231548d1_ex99-1img02.jpg GRAPHIC begin 644 tm2231548d1_ex99-1img02.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Nov. 30, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 30, 2022
Entity File Number 001-40674
Entity Registrant Name MaxCyte, Inc.
Entity Central Index Key 0001287098
Entity Tax Identification Number 52-2210438
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 9713 Key West Avenue
Entity Address, Address Line Two Suite 400
Entity Address, City or Town Rockville
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20850
City Area Code 301
Local Phone Number 944-1700
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 par value
Trading Symbol MXCT
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 9 tm2231548d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001287098 2022-11-30 2022-11-30 iso4217:USD shares iso4217:USD shares 0001287098 false 8-K 2022-11-30 MaxCyte, Inc. DE 001-40674 52-2210438 9713 Key West Avenue Suite 400 Rockville MD 20850 301 944-1700 false false false false Common Stock, $0.01 par value MXCT NASDAQ true false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://maxcyte.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2231548d1_8k.htm mxct-20220630.xsd mxct-20220630_lab.xml mxct-20220630_pre.xml tm2231548d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2231548d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm2231548d1_8k.htm" ] }, "labelLink": { "local": [ "mxct-20220630_lab.xml" ] }, "presentationLink": { "local": [ "mxct-20220630_pre.xml" ] }, "schema": { "local": [ "mxct-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "MXCT", "nsuri": "http://maxcyte.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2231548d1_8k.htm", "contextRef": "From2022-11-30to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://maxcyte.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2231548d1_8k.htm", "contextRef": "From2022-11-30to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 16 0001104659-22-123467-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-123467-xbrl.zip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